{"id":56028,"date":"2026-05-19T07:00:00","date_gmt":"2026-05-19T00:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=56028"},"modified":"2026-05-19T07:00:00","modified_gmt":"2026-05-19T00:00:00","slug":"accro-bioscience-announces-50-million-series-c-financing-led-by-orbimed-to-advance-clinical-pipeline-for-immune-mediated-diseases","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=56028","title":{"rendered":"Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases"},"content":{"rendered":"<ul type=\"disc\">\n<li><b>F<\/b><b>inancing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza<\/b><\/li>\n<li><b>Proceeds will advance<\/b><b> multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">NEW YORK and SUZHOU, China<\/span>, May 19, 2026 \/PRNewswire\/ &#8212; Accro\u00a0Bioscience Inc. (&#8220;Accro Bioscience&#8221;), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune mediated diseases, <span><\/span>announced the closing of its $50 million Series C financing. The round was led by OrbiMed, with participation from TCG Crossover (&#8220;TCGX&#8221;), LAV, Cenova Capital, and existing investors Shenzhen Capital Group (&#8220;SCGC&#8221;) and Oriza Holdings (&#8220;Oriza&#8221;).<\/p>\n<p>Proceeds from the financing will fund the Phase IIb clinical trial of AC-101, a leading RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&amp;I diseases.<\/p>\n<p><b>Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, said<\/b><b>:<\/b> &#8220;We at Accro Bioscience are focused on our mission of delivering innovative oral treatments for the millions of patients living with immune mediated diseases. I&#8217;m grateful to our investors who share our vision and have supported us continuously.&#8221;<\/p>\n<p><b>Steven Wang, Ph.D., CFA, Partner at OrbiMed, said:<\/b> &#8220;We are highly impressed by Accro Bioscience&#8217;s innovative pipeline. The team&#8217;s scientific acumen and track record of strong execution were instrumental in our decision to invest. OrbiMed is excited to partner with Accro to accelerate their global clinical development.&#8221;<\/p>\n<p><b>About AC-101<\/b><\/p>\n<p>AC-101 is a novel, selective RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD\/RIPK2 is implicated in several inflammatory and autoimmune diseases. AC-101 was developed from Accro <span>Bioscience&#8217;s<\/span> proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK\/PD profile. A Phase\u00a0Ib\/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND clearance from U.S. FDA for a Phase II clinical trial.<\/p>\n<p><b>About Accro Bioscience<\/b><\/p>\n<p>Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company&#8217;s robust pipeline of first- and best-in-class compounds offers the potential for innovative, paradigm-shifting therapies.<\/p>\n<p>For more information, please visit <a href=\"http:\/\/www.accropeutics.com\/\" target=\"_blank\" rel=\"nofollow\"><span>www.accropeutics.com<\/span><\/a>.<\/p>\n<p><b>About OrbiMed<\/b><\/p>\n<p>OrbiMed is a leading healthcare investment firm, with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty\/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed&#8217;s team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.orbimed.com\/\" target=\"_blank\" rel=\"nofollow\">www.orbimed.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li><b>F<\/b><b>inancing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza<\/b><\/li>\n<li><b>Proceeds will advance<\/b><b> multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">NEW YORK and SUZHOU, China<\/span>, May 19, 2026 \/PRNewswire\/ &#8212; Accro\u00a0Bioscience Inc. (&#8220;Accro Bioscience&#8221;), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune mediated diseases, <span><\/span>announced the closing of its $50 million Series C financing. The round was led by OrbiMed, with participation from TCG Crossover (&#8220;TCGX&#8221;), LAV, Cenova Capital, and existing investors Shenzhen Capital Group (&#8220;SCGC&#8221;) and Oriza Holdings (&#8220;Oriza&#8221;).<\/p>\n<p>Proceeds from the financing will fund the Phase IIb clinical trial of AC-101, a leading RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for I&amp;I diseases.<\/p>\n<p><b>Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, said<\/b><b>:<\/b> &#8220;We at Accro Bioscience are focused on our mission of delivering innovative oral treatments for the millions of patients living with immune mediated diseases. I&#8217;m grateful to our investors who share our vision and have supported us continuously.&#8221;<\/p>\n<p><b>Steven Wang, Ph.D., CFA, Partner at OrbiMed, said:<\/b> &#8220;We are highly impressed by Accro Bioscience&#8217;s innovative pipeline. The team&#8217;s scientific acumen and track record of strong execution were instrumental in our decision to invest. OrbiMed is excited to partner with Accro to accelerate their global clinical development.&#8221;<\/p>\n<p><b>About AC-101<\/b><\/p>\n<p>AC-101 is a novel, selective RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD\/RIPK2 is implicated in several inflammatory and autoimmune diseases. AC-101 was developed from Accro <span>Bioscience&#8217;s<\/span> proprietary drug discovery platform targeting regulatory cell death and inflammation. AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating a favorable safety and PK\/PD profile. A Phase\u00a0Ib\/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The Company has received the IND clearance from U.S. FDA for a Phase II clinical trial.<\/p>\n<p><b>About Accro Bioscience<\/b><\/p>\n<p>Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company&#8217;s robust pipeline of first- and best-in-class compounds offers the potential for innovative, paradigm-shifting therapies.<\/p>\n<p>For more information, please visit <a href=\"http:\/\/www.accropeutics.com\/\" target=\"_blank\" rel=\"nofollow\"><span>www.accropeutics.com<\/span><\/a>.<\/p>\n<p><b>About OrbiMed<\/b><\/p>\n<p>OrbiMed is a leading healthcare investment firm, with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty\/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed&#8217;s team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.orbimed.com\/\" target=\"_blank\" rel=\"nofollow\">www.orbimed.com<\/a>.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-56028","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/56028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56028"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/56028\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}